Filing search / Ikena Oncology Inc / "Scarcity"

10-K

2021 FY

IKNA Ikena Oncology Inc

17 Mar 22

Annual report

6:31am

develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available

424B4

IKNA Ikena Oncology Inc

26 Mar 21

Prospectus supplement with pricing info

5:04pm

by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological

S-1/A

IKNA Ikena Oncology Inc

22 Mar 21

IPO registration (amended)

8:51am

to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available to date. Early use

S-1

IKNA Ikena Oncology Inc

5 Mar 21

IPO registration

2:59pm

by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib

DRS/A

e44e3ssdjk6peatrpv5

11 Feb 21

Draft registration statement (amended)

12:00am

DRS

zntwf60m18r

8 Jan 21

Draft registration statement

12:00am